655. Multiple Myeloma: Cellular Therapies: Poster II

Trial in progress QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel arlo cel in patients with relapsed refractory multiple myeloma RRMM

CAR hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs ide cel and cilta cel

TPO ras for persistent thrombocytopenia following CAR T therapy in multiple myeloma A multicenter clinical experience

Peripheral circulating myeloma cells accurately identify bone marrow MRD positivity in multiple myeloma patients receiving CAR T or autologous transplant

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma The first real world data from a single Chinese center

The allogeneic fully human anti CD38 CAR γδ T cells enable off the shelf CAR T cell therapy for myeloma

Innovative sdab based CAR T cells targeting BCMA outperform current CAR T therapies for multiple myeloma

Pharmacokinetics  pharmacodynamics and biomarkers of lbl 034 a GPRC5D targeted T cell engager in a first in human phase Ⅰ Ⅱ study in relapsed refractory multiple myeloma

Identifying high risk profiles and adverse prognoses in relapsed refractory multiple myeloma treated with bispecific antibodies A real world analysis of 943 treatment initiations